EUVIMEDEUVIMED entdecken
Crossref

Evidence-Based Clinical Protocols to Monitor Efficacy of [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data

Lena M Unterrainer, Nicolas De Leiris, Marcus Unterrainer, Astrid Delker, Linus Hempel, Zachary Ells, Sophie C Kunte, Josef Zahner, Adrien Holzgreve, Mathias J Zacherl, Gabriel T Sheikh, Jozefina Casuscelli und 14 weitere

Journal of Nuclear Medicine · 24.04.2025 · jnumed.124.269431

DOI: 10.2967/jnumed.124.269431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 24.04.2025. Verfasst von Lena M Unterrainer und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Radiopharmaceuticals, Evidence-Based Medicine. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our objectives were to assess the prognostic value of posttherapy [177Lu]Lu-PSMA (LuPSMA) SPECT/CT by visual evaluation using RECIP 1.0 during LuPSMA therapy and develop an evidence-based clinical protocol to monitor the efficacy of LuPSMA.

Methods

Patients with metastatic castration-resistant prostate cancer who received at least 2 LuPSMA cycles between April 2019 and November 2023 were retrospectively included in this study. Pairs of baseline and interim LuPSMA SPECT/CT (SPECT) and PSMA PET/CT (PET) images after 2 therapy cycles were analyzed per visual RECIP 1.0. Changes in prostate-specific antigen (PSA) levels at 12 wk were categorized by Prostate Cancer Working Group Criteria 3 guidelines and combined with RECIP 1.0 reads to determine disease progression using a composite classification method (PSA + RECIP). The primary outcome was the prognostic value of posttherapeutic SPECT by RECIP 1.0 for overall survival (OS). The clinical protocol was developed on the basis of the prognostic accuracy (Harrell concordance index, or C-index) of SPECT versus PET and the combination of SPECT plus PSA (SPECT + PSA) versus the combination of PET plus PSA (PET + PSA).

Results

Data from 105 patients were evaluated. Progressive disease determined by SPECT was associated with shorter OS compared with stable disease (hazard ratio, 2.5; 95% CI, 1.2-5.3; P = 0.015) and with partial response (hazard ratio, 6.5; 95% CI, 2.7-15.7; P < 0.001). Of the 73 patients who underwent PET after 2 cycles, 7 (10%), 30 (41%), 22 (30%), and 30 (41%) had tumor progression shown by SPECT, PET, SPECT + PSA, and PET + PSA, respectively. The C-index for SPECT was inferior compared with that for PET (0.54 vs. 0.66; P < 0.001), whereas the C-indices for SPECT + PSA and PET + PSA did not differ significantly (0.62 vs. 0.66, respectively; P = 0.07).

Conclusion

Posttherapeutic LuPSMA SPECT/CT per RECIP 1.0 after 2 therapy cycles was prognostic for OS. LuPSMA SPECT/CT identified significantly fewer patients with RECIP-classified progressive disease; however, SPECT + PSA achieved similar prognostic accuracy to PET + PSA for LuPSMA response evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantLutetiumRadiopharmaceuticalsEvidence-Based MedicineHumansMaleAgedRetrospective StudiesNeoplasm MetastasisMiddle AgedTreatment OutcomeRadioisotopesAged, 80 and overClinical ProtocolsProstate-Specific AntigenSingle Photon Emission Computed Tomography Computed TomographyPrognosis

Stichwörter der Autor:innen

LuPSMAPSMA PET/CTRECIPSPECT/CTradiopharmaceutical therapyresponse biomarker

Substanzen

LutetiumRadiopharmaceuticalsLutetium-177RadioisotopesPluvictoProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Hospital LMU Munich, Munich, Germany.
  • Bavarian Cancer Research Center, Partner Site Munich, Munich, Germany.
  • Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
  • Nuclear Medicine Department, University Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, Grenoble, France.
  • Department of Radiology, University Hospital LMU Munich, Munich, Germany.
  • Department of Urology, University Hospital LMU Munich, Munich, Germany.

Zitieren

APA

Unterrainer, L. M., De Leiris, N., Unterrainer, M., Delker, A., Hempel, L., Ells, Z., Kunte, S. C., Zahner, J., Holzgreve, A., Zacherl, M. J., Sheikh, G. T., Casuscelli, J., Leenhardt, J., Pienta, K. J., Jacquet, E., Laramas, M., Long, J., Faure, M., Reboulet, G., …, & Djaileb, L. (2025). Evidence-Based Clinical Protocols to Monitor Efficacy of [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data. Journal of Nuclear Medicine, jnumed.124.269431. https://doi.org/10.2967/jnumed.124.269431

Vancouver

Unterrainer LM, De Leiris N, Unterrainer M, Delker A, Hempel L, Ells Z, et al. Evidence-Based Clinical Protocols to Monitor Efficacy of [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data. Journal of Nuclear Medicine. 2025:jnumed.124.269431. doi:10.2967/jnumed.124.269431

BibTeX
@article{Unterrainer2025,
  author = {Unterrainer, Lena M and De Leiris, Nicolas and Unterrainer, Marcus and Delker, Astrid and Hempel, Linus and Ells, Zachary and Kunte, Sophie C and Zahner, Josef and Holzgreve, Adrien and Zacherl, Mathias J and Sheikh, Gabriel T and Casuscelli, Jozefina and Leenhardt, Julien and Pienta, Kenneth J and Jacquet, Emmanuelle and Laramas, Mathieu and Long, Jerome and Faure, Marine and Reboulet, Ghislaine and Paller, Channing J and Mercier, Alexis and Solnes, Lilja B and Kiraz, Kevin and Ilhan, Harun and Gafita, Andrei and Djaileb, Loïc},
  title = {Evidence-Based Clinical Protocols to Monitor Efficacy of [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  pages = {jnumed.124.269431},
  doi = {10.2967/jnumed.124.269431}
}
Kostenlos starten →